Program Title:  Advances in the Treatment of Myelosuppression and Anemia

Release Date: 9/19/2006

Valid Through: 9/18/2007

Target Audience:This CME activity is designed for oncology surgeons, medical oncologists, and other healthcare professionals who treat myelosuppression and anemia.

Learning Objectives

After completing this educational activity, participants should be better able to:

• Discuss the issues surrounding different timing of dosing of pegfilgrastim.
• Realize the potential importance of parenteral iron on improving response rates to ESP therapy
• Understand that the pediatric population derives the same benefits from pegfilgrastim as filgrastim.
• Discuss the potential use of darbepoetin alfa in the treatment of MDS.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Creative Educational Concepts, Inc. (CEC) and OncoEd, Inc. CEC is accredited by the ACCME to provide continuing medical education for physicians. CEC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CEC is an equal opportunity/affirmative action institution.

Fee:There is no fee for this activity.

Instructions for Participation

This activity was released September 19, 2006, and will be valid through September 18, 2007. There are no fees for participating and receiving credit for this activity. To successfully complete this activity, participants must do the following:

• Read the target audience, learning objectives, and author disclosures.
• Study the educational activity online or printed out.
• Read, complete, and submit answers to the post test questions and evaluation questions online and click "submit" when finished.
• After clicking "submit," your online certificate will be made available for you to view and print.

Hardware/Software Requirements

This Website requires version 4.x browsers or higher from Microsoft or Netscape. It has been optimized for Microsoft Browsers.

Privacy and Confidentiality

CancerConsultants is committed to respecting your privacy. We've structured our Web site so that you can visit CancerConsultants on the Web without identifying yourself or revealing any personal information. If you choose to provide us personally identifiable information, you can be assured that it will only be used to support your relationship with CancerConsultants.

On some CancerConsultants Web pages, you can make requests, and register to receive materials. The types of personal information collected at these pages are name and contact information. In order to tailor our subsequent communications to you and continuously improve our products and services, we may also ask you to voluntarily provide us with information regarding your experience with cancer, personal or professional interests, demographics and contact preferences.

CancerConsultants is committed to ensuring the security of your information. To prevent unauthorized access, maintain data accuracy, and ensure the appropriate use of information, we have put in place appropriate physical, electronic, and managerial procedures to safeguard and secure the information we collect online.

CancerConsultants has links to many other sites and cannot ensure the privacy or security of information you provide to the linked site.

If you have comments or questions about our privacy policy, please send them to this email address: mail@cancerconsultants.com.

Faculty and Disclosures

CEC is committed to the provision of CME that is balanced, objective, and evidence based. CEC adheres to Accreditation Council for Continuing Medical Education (ACCME) Essentials and Standards. Accordingly, all parties involved in content development have disclosed any real or apparent conflicts of interest relating to the topics of this educational activity and the disclosure summary follows. CEC has established mechanisms to resolve conflicts of interest should they arise. Participants in CEC CME programs are afforded the opportunity to provide feedback on the quality of individual programs.

Author: John Glaspy, MD
Disclosure: Dr. Glaspy has disclosed that he has received Research Support from Amgen, and Ortho Biotech.

Editor: Adam C. Tanous, Director and Managing Editor, OncoEd, Inc.
Disclosure: Mr. Tanous has no relevant financial interests to disclose.

Disclaimer

Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-CEC information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC.

Investigational and/or off-label use of commercial products and devices

CEC requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

The presentations in this CME activity might include discussion of investigational and/or unlabeled use of drugs. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Supporters

This activity is supported by an unrestricted educational grant from Amgen.